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In contrast to the established role of epidermal growth factor receptor (EGFR) inhibitors 
for the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring 
activating EGFR mutations, the role of EGFR blockade and of EGFR molecular testing in 
the second-line treatment remains less clear. The irreversible pan-ErbB family inhibitor 
afatinib (Gi(l)otrif®) was recently FDA- and EMA-approved for the second-line treatment 
of NSCLC with squamous cell histology irrespective of the EGFR mutational status (LUX-
Lung 8). Contrariwise, results from the TAILOR and DELTA trials among retrospective 
biomarker analyses show the predictive value of the EGFR mutational status for efficacy 
of reversible EGFR inhibitors also as a second-line therapy. This mini review critically 
summarizes the current role of EGFR-targeting strategies in the second-line treatment 
of NSCLC with special respect to afatinib in light of emerging T790M-specific EGFR and 
immune check point inhibitors. The review also emphasizes the urgent need for reliable 
biomarkers to guide therapeutic decision-making and outlines prospective changes to 
the second-line landscape with some of the current second-line treatment concepts 
likely to be moved to the first-line.
Keywords: afatinib, eGFR mutation, TKi, second-line treatment, nSCLC, squamous cell carcinoma, 
T790M-specific inhibitors, checkpoint blockade
inTRODUCTiOn
Over the past decade, various genomic alterations relevant for non-small cell lung cancer (NSCLC) 
biology (“oncogene addiction”) were discovered and have subsequently changed the treatment para-
digm from a histology-oriented to a biomarker-driven approach [reviewed by Thomas et al. (1)]. 
Historically, docetaxel was the gold standard second-line treatment (2) until erlotinib (Tarceva®), 
a first-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) 
was FDA-approved in 2004 as maintenance therapy and for second and subsequent line treatment, 
after failure of chemotherapy in unselected patients (3). In the meantime, several phase-III trials 
compared EGFR TKIs with chemotherapy and have established EGFR TKIs as the standard first-
line treatment for patients with EGFR-mutant NSCLC (4–7). Nowadays, not less than three EGFR 
TKIs—erlotinib, gefitinib (Iressa®) and the pan-ErbB family inhibitor afatinib (Giotrif®)—are 
licensed for the first-line treatment. Drug reimbursement is bound to the presence of a com-
mon activating EGFR mutation (i.e., exon 19 deletions and L858R point mutations) detected by 
FDA-approved tests [erlotinib—cobas®; gefitinib (Iressa®) and afatinib (Gi(l)otrif®)—therascreen 
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EGFR RGQ]. However, the relevance of EGFR mutations for the 
second-line decision-making process remained less clear, and 
erlotinib (for all NSCLC) as well as afatinib (for squamous cell 
histology only) have initially been FDA-approved irrespective 
of EGFR mutational status or other predictive markers (3, 8). 
Several recent prospective clinical trials (TAILOR, DELTA) and 
retrospective biomarker analyses challenge this broad approval 
and emphasize the need for EGFR mutational re-testing ahead 
of the second-line therapy if not performed at diagnosis (9, 10).
eviDenCe FOR CLiniCAL eFFiCACY OF 
eGFR TKis in THe SeCOnD Line
The use of first-generation EGFR TKIs like erlotinib and gefitinib 
in the second-line treatment of patients with EGFR-mutant 
NSCLC is supported by prospective single-arm studies, retro-
spective biomarker analyses of phase-II studies and subgroup 
analyses from phase-III studies (11–20). Several randomized 
trials have compared single-agent EGFR TKIs with single-agent 
chemotherapy and showed an improvement in progression-free 
survival (PFS) but mostly not in overall survival (OS) with 
chemotherapy compared with EGFR TKIs in an EGFR wild-
type population (9, 10, 19, 21–28). Afatinib has been tested in 
the worldwide LUX-Lung trial program and second-line stud-
ies included LUX-Lung 2 (first- or second-line, single-arm), 
LUX-Lung 4 (second-line or beyond), and the head-to-head 
comparison with erlotinib in LUX-Lung 8 (second-line) (8, 29). 
Afatinib like dacomitinib (the latter is not FDA-approved yet) 
irreversibly inhibits all ErbB family members and was supposed 
to overcome resistance mediated by secondary EGFR T790M 
mutations (30) which occur in ~50–60% of cases upon progres-
sion with reversible EGFR TKIs (31). Both drugs demonstrated 
promising activity against T790M in preclinical models but failed 
to overcome T790M-mediated resistance in patients due to dose-
limiting toxicity resulting from inhibition of wild-type EGFR 
(32). Furthermore, analyses of small numbers of re-biopsy sam-
ples suggest that treatment with afatinib in the first-line results 
in similar rates (~50–60%) of secondary T790M mutations upon 
progression compared to reversible EGFR TKIs (31, 33). This 
may be due to the high frequency (up to 80%) of pretreatment 
EGFR T790M mutations (34). However, the results from LUX-
Lung 4 and 5 suggested that some patients not only may benefit 
from afatinib after acquired resistance to gefitinib/erlotinib but 
also from continued ErbB inhibition during chemotherapy 
versus switching to single-agent chemotherapy after progression 
with EGFR TKIs (35). The LUX-Lung 5 results have yet not let to 
changes in second-line treatment recommendations in terms of 
combining EGFR inhibition with cytotoxic chemotherapy post-
progression in patients with EGFR-mutant NSCLC who initially 
responded to EGFR TKI treatment.
AFATiniB in nSCLC wiTH SQUAMOUS 
CeLL HiSTOLOGY
Currently, treatment paradigms are most dramatically changing 
in tumors with squamous cell histology. This entity has unmet 
medical needs even though the incidence in Western countries 
is decreasing (25% of all lung cancer cases). Reflecting the 
tobacco carcinogenesis, tumors are genomically complex yet 
EGFR mutations are sporadic, and EGFR molecular testing is not 
routinely performed in this subgroup (36). Molecular analyses 
indicated that pan-ErbB blockade could be of therapeutic benefit 
in squamous cell tumors due to multiple genetic aberrations 
in ErbB receptors (HER2: 4%, HER3: 2%) and in downstream 
signaling molecules (KRAS: 3%, HRAS: 3%, BRAF: 4%, NF1: 
11%, NRG1) (36). Furthermore, 20–30% of tumors overexpress 
HER2 and HER3. Whereas erlotinib was the only approved 
second-line TKI in squamous cell lung cancer since 2004, 
afatinib received FDA- and EMA-approval for the second-line 
treatment of squamous cell NSCLC in 2016 based on results of 
the head-to-head (against erlotinib) study LUX-Lung 8 (8). This 
approval is irrespective of the intratumoral EGFR mutational 
status. Supposedly, the improved OS [median 7.9  months 
(95% CI 7.2–8.7) versus 6.8  months (5.9–7.8); HR 0.81 (95% 
CI 0.69–0.95), p = 0.0077] is unlikely driven by the inhibition 
of mutant EGFR which was found in only 6% of the patients 
but rather by the broader irreversible pan-ErbB blockade with 
afatinib compared to erlotinib.
newLY eMeRGinG THiRD-GeneRATiOn 
eGFR inHiBiTORS AnD iMMUne 
CHeCKPOinT BLOCKADe in THe 
SeCOnD-Line TReATMenT
After second-generation EGFR TKIs failed to effectively 
overcome T790M-mediated resistance in the clinical setting, 
drugs that specifically inhibit EGFR T790M without affecting 
wild-type EGFR were developed subsequently. Osimertinib 
(Tagrisso®), a EGFR T790M-specific kinase inhibitor, inhibits 
EGFR exon 18, 19, and 21 mutations and the drug-resistant 
T790M mutation and received accelerated FDA approval in 
2015. Response rates to osimertinib in patients with T790M-
positive tumors after first-generation EGFR TKI are comparable 
to those with first-line EGFR TKI (58–61%) and the median PFS 
reached 9.6 months compared to 2.8 months in EGFR T790M-
negative patients. Osimertinib has a better toxicity profile than 
first- and second-generation EGFR TKI due to the reduced 
wild-type EGFR inhibition. Common adverse events are class-
specific (i.e., diarrhea, rash, nail toxicity) but were generally 
mild to moderate (37).
Other promising therapeutic concepts that experienced a tre-
mendous renaissance especially in squamous cell NSCLC include 
the modulation of the tumor vasculature [anti-VEGFR-2 antibody 
ramucirumab (Cyramza®), REVEL trial] (38) and of the immune 
environment. The latter strategy enhances the patient’s natural 
immune response to cancer mainly via CD8+ cells. Cytotoxic 
T-lymphocyte-associated protein-4 (CTLA-4) and programmed 
cell death protein (PD-1) have been identified as important 
targets which are expressed on activated T cells and interact with 
ligands on antigen-presenting cells thereby limiting the immune 
response. Both, the anti-PD-1 monoclonal antibody Nivolumab 
(Opdivo®) (39, 40) and pembrolizumab (Keytruda®) (41) have 
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been FDA-approved for PD-L1-positive (defined as a tumor 
proportion score ≥  50%) metastatic squamous (nivolumab) or 
squamous and non-squamous (pembrolizumab) NSCLC lacking 
EGFR or ALK mutations with progression to platinum-based 
chemotherapy. Other antibodies targeting PD-L1 like atezoli-
zumab (MPDL3280A) confirm the efficacy of this innovative 
concept of immune checkpoint blockade (42).
COnCLUSiOn AnD OUTLOOK
Compared to the their role in the first-line, reversible (erlotinib, 
gefitinib) and irreversible (afatinib) EGFR TKIs have relatively less 
impact on the second-line treatment of patients with advanced 
NSCLC. Afatinib, however, was recently approved for patients 
with squamous cell NSCLC irrespective of the EGFR mutational 
status. With the advent of innovative treatment concepts as e.g., 
immune checkpoint blockade or T790M-specific EGFR inhibi-
tion, it is likely that EGFR TKIs will be further pushed into the 
first-line where they already today face ongoing head-to-head 
comparisons with the EGFR T790M-specific inhibitor osimer-
tinib to identify the most effective upfront treatment option for 
patients with EGFR-mutant NSCLC (e.g., FLAURA trial: osimer-
tinib versus gefitinib or erlotinib).
Currently, patients with EGFR-mutant tumors should be 
treated with EGFR TKIs as soon as possible, ideally in the 
first-line setting. This is supported by several first-line phase-III 
clinical trials, which showed higher response rates (>70%) (5, 43) 
as if the EGFR TKI was given in the second-line (27–67.4%) even 
though some of the reported data on response rates have been 
conflicting (5, 18, 19, 43, 44). Apart from the pooled LUX-Lung 
3 and 6 analyses, all EGFR TKI first-line trials failed to show an 
OS benefit (45). This is likely confounded by crossover of patients 
to EGFR TKI post-progression to first-line chemotherapy. From 
the only prospective randomized TORCH trial which compared 
first-line EGFR TKI followed by chemotherapy with first-line 
chemotherapy followed by second-line EGFR TKI, the authors 
concluded, that patients with EGFR mutations would experience 
greater benefit from first-line EGFR TKI followed by second-line 
chemotherapy. However, patients in this study were not selected 
by EGFR mutational status (only 14.2% were EGFR mutation 
positive) and the small sample size as well as the fact that only 
60% of patients in both arms received second-line treatment 
furthermore confounded the result (46). Numerous arguments 
yet support the application of EGFR TKI in the first-line over 
second-line: quality of life during EGFR TKI treatment is bet-
ter compared to first-line chemotherapy especially in patients 
with poor performance status, whole-brain irradiation with its 
detrimental consequences on cognitive functions for patients 
with brain metastasis may be delayed by EGFR TKIs (47–49) and 
giving EGFR TKIs upfront increases the chance of TKI exposure 
for those patients whose tumors harbor the target. This is sup-
ported by the fact that about 1/3 of patients with EGFR mutations 
assigned to first-line chemotherapy did not receive EGFR TKI as 
salvage therapy in IPASS, WJTOG 3405, and OPTIMAL (4, 6, 
50). LUX-Lung 6 reported the longest PFS (13.7 months) of all 
first-line EGFR TKIs and two head-to-head comparison studies 
[LUX-Lung 7 (first-line) and 8 (second-line)] were slightly in 
favor of afatinib over erlotinib and gefitinib even though there 
was some criticism about the interpretation of results and the 
publication strategy (26). Nevertheless, these trials indicate that 
afatinib is a highly effective drug in this setting but comes with 
numerically higher side effect rates compared to erlotinib and 
gefitinib (8, 51, 52). These toxicities are effectively manageable by 
supportive measures (53, 54) and tolerability-guided dose reduc-
tions which do not affect therapeutic efficacy (55). Especially 
afatinib, however, will be confronted with EGFR T790M-specific 
inhibitors like osimertinib in the first-line setting as the latter 
have a more favorable toxicity profile due to less wild-type EGFR 
inhibition.
If EGFR mutational testing has not been performed ahead of 
the first-line therapy—it is estimated that 15 to 35% of patients 
have insufficient tumor tissue for genotyping (56, 57), patients 
should be considered for repeated testing before starting 
second-line therapy. Plasma-genotyping, a technique that uses 
cell-free (cf)DNA, may be an important alternative to the clas-
sical biopsy approach in this scenario (58, 59) and it is highly 
likely that “liquid biopsies” will become available for many 
known oncogenic and resistance mutations in the near future. 
This may substantially change the decision-making process as 
liquid biopsies will enable the physician to monitor development 
of resistance more promptly and to decide more accurately on 
therapeutic consequences (60). TAILOR, DELTA, and other 
trials indicate the predictive value of EGFR mutational status on 
EGFR TKIs in the second-line (9, 10). In particular, the TAILOR 
study clearly suggests that second-line docetaxel is superior to 
erlotinib in terms of survival in all patients with EGFR wild-type 
NSCLC who are able to tolerate toxicities of chemotherapy. 
DELTA and other trials (CTONG0806 (28) and NCT01783834 
(61): pemetrexed versus gefitinib) as well as a meta-analysis by 
Li et al. (62) point into the same direction with a better PFS for 
second-line chemotherapy in EGFR wild-type patients. On the 
contrary, there is evidence to suggest that patients with EGFR-
mutant NSCLC who are still TKI naive perform better with EGFR 
TKIs (9, 10, 19, 21–28). In this context, reacting to the JUNO trial 
results (not fully published yet), FDA restricted the indication 
for erlotinib as maintenance or second or greater line treatment 
to those NSCLC patients whose tumors harbor common EGFR 
mutations in October 2016.
If the EGFR mutation status remains unknown for the second-
line treatment decision, a preferred strategy would be to offer 
nivolumab for squamous NSCLC or pembrolizumab for squa-
mous and non-squamous histology (after platinum-based chem-
otherapy if PD-L1 expression ≥ 50%). The approval of immune 
checkpoint inhibitors will consequently push docetaxel—long 
the standard of care treatment in the second-line—to the third-
line or even beyond. Especially for squamous cell NSCLC, based 
on the positive survival results of the SQUIRE study which tested 
the human EGFR monoclonal antibody necitumumab in combi-
nation with cisplatin-gemcitabine chemotherapy, the treatment 
might soon change even in the first-line setting (63). Big efforts 
are furthermore ongoing to advance biomarker-driven therapies 
for patients with squamous cell carcinoma of the lung within 
the Lung-MAP studies (64) and it is also not a far-fetched vision 
that immune checkpoint inhibitors will have a role in untreated 
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advanced lung cancer. Currently, more than 10 randomized tri-
als (among them KEYNOTE, CHECKMATE, IMPOWER) are 
ongoing and the question will rather be how checkpoint inhibi-
tors will integrate into the upfront setting, as monotherapy or in 
concurrent or sequential combination with chemotherapy.
Other important questions remain that may open up new 
indications for afatinib, but also other EGFR TKIs as to which 
drug is most effective in controlling brain metastases and rare 
EGFR mutations. It is known, that patients with EGFR muta-
tions have an increased risk especially for leptomeningeal tumor 
dissemination (65, 66). Penetration of the blood-brain barrier 
as well as clinical efficacy have been described for both afatinib 
(47–49) and osimertinib (67). Other EGFR inhibitors with high 
in vivo CNS penetration (e.g., AZD3759) are currently under 
early clinical phase evaluation. To determine the most effective 
drug for CNS disease, also more systematic investigation of the 
mutational spectrum in brain metastases is required. In this 
context, surprisingly, a restrospective study found the majority 
of CNS and leptomeningeal metastases to be negative for EGFR 
T790M despite of T790M positivity in the extracranial tumor 
(spatiotemporal heterogeneity) (68). This may argue against 
T790M-specific and rather for first- or second-generation 
EGFR TKIs.
Another field of current interest are less common EGFR muta-
tions which together represent about 10% of all EGFR mutations 
(69). Especially afatinib may be a good option for these rare 
EGFR mutations that include exon 18-21 duplications, G719X, 
Del18, E709K, insertions in exon 19, S768I, or L861Q as erlo-
tinib, osimertinib and gefitinib showed only moderate activities 
in these mutations (70, 71, 72). Osimertinib contrariwise may be 
effective in rare exon 20 insertions whereas nazartinib (EGF816) 
shows promising efficacy in the majority of exon 20 mutations. 
The quinazoline-based EGFR inhibitors, gefitinib and afatinib 
finally proofed efficacy in tumors containing a common EGFR 
mutation (i.e., Del19 or L858R), in conjunction with L718Q, 
L844V, or C797S (73, 74).
To summarize, treatment paradigms for NSCLC patients in 
the second-line are currently experiencing dramatic changes. 
Many of the currently tested innovative concepts will likely move 
forward to the first-line treatment, whereas other strategies and 
possibly indications for EGFR TKIs (as, e.g., continued ErbB 
blockade post-progression, TKI-specific efficacy in rare muta-
tions) may be established in the second-line. One necessity that all 
therapeutic concepts and treatment lines share in common is the 
urgent need for reliable predictive factors in times of increasing 
treatment costs. These are still not available for anti-angiogenic 
agents like ramucirumab and it remains unclear, if any predictive 
biomarker will help to select patients with squamous cell NSCLC 
for afatinib treatment in the future.
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